A medical expert examines an extreme body condition involving severe skin fragility and explains the underlying disorder.

The U.S. Food and Drug Administration has approved Abeona Therapeutics' Zevaskyn (prademagene zamikeracel) for patients with the rare, genetic skin disorder recessive dystrophic epidermolysis bullosa.

Add Yahoo as a preferred source to see more of our stories on Google. SALT LAKE CITY (ABC4) — A Utah woman is sharing her story after she survived an incredibly rare and often fatal skin disorder ...

Poster #76954 highlights QTORIN™ rapamycin’s single phase anhydrous gel formulation designed to optimize dermal bioavailability of rapamycin for mTOR-driven skin diseases while overcoming the ...

People with Sweet's syndrome often wake up with a fever, body aches, and blisters on their neck, limbs and face. Also known as acute febrile neutrophilic dermatosis, it is an inflammatory skin disease ...

MMP patients have a significantly increased risk of SCC, BCC, and NMSC, particularly with severe disease. The study analyzed data from over 117 million individuals, using propensity-score matching for ...

Every summer, Alberto Gomez lives with a fear most people never consider. As Spain's increasingly intense summers bring more ...

Quoin Pharmaceuticals Ltd. has announced the filing of U.S. and International patent applications for new topical formulations of rapamycin aimed at treating rare diseases such as microcystic ...

After a poor showing of its COVID med vilobelimab in a rare skin disorder trial, German drugmaker InflaRx is going back to the drawing board. The independent data monitoring committee assessing a ...

Cutaneous mastocytosis is one of two types of mastocytosis, a rare disorder in which too many mast cells — a type of white blood cell that helps the immune system function properly — accumulate in the ...